Over the last few months, the focus of the different Working Parties remains unwavering on delivering cutting edge practical data and transplant guidelines. This focus is mainly based on the real-life experience gathered within the EBMT registry, as well as on the optimal management of transplant patients, especially with the advent of numerous targeted therapies which are being used before and after transplantation (e.g. ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with CLL or mantle cell lymphoma; brentuximab vedotin prior and/or after allogeneic stem cell transplantation in Hodgkin lymphoma). The haplo-identical transplant approach continues to be an ever-evolving strategy that has been experiencing an impressive boom, particularly in acute leukaemia. It is already proving to be a valid transplant modality with outcomes similar to those achieved with other stem cell sources and donors (e.g. unmanipulated haploidentical versus matched sibling donor in patients with AML in CR1; haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory AML, etc.).
At the same time, the EBMT registry is a timeless gateway to investigating the role of stem cell transplantation in rare disease entities or complications (e.g. IPEX syndrome, transplant-associated microangiopathy, outcome of patients receiving salvage third autologous stem cell transplantation in multiple myeloma, donor cell-derived leukaemia/MDS following stem cell transplantation, etc.)
The EBMT is committed to generating novel and important research data, and always does so under the premise of continuous evaluation of transplant practices (e.g. activity survey on the use of unrelated donor transplantation), incorporation of the latest technological advances into the field (e.g. development of the eGVHD app in assessing the severity of GVHD), and close collaboration with other sister societies (e.g. role of autologous stem cell transplantation in severe Crohn's disease).